摘要
探讨短期胰岛素强化治疗对新诊断2型糖尿病（T2DM）患者血浆脂蛋白相关性磷脂酶A2（Lp－PLA2）及分泌型磷脂酶A2（sPLA2）水平的影响及其临床意义。90例新诊断T2DM患者接受胰岛素泵持续皮下输注胰岛素治疗（CSII）2周，治疗后sPLA2较治疗前显著降低[173.78（80.95，278.09）μg/L比219.33（130.03，337.30） μg/L ，P〈0.01]，而Lp－PLA2水平降低不显著[88.35（76.74，125.18）μg/L比102.9（76.34，134.31）μg/L，P〉0.05]，但二者治疗前后水平的变化与稳态模型评估的胰岛素抵抗（HOMA－IR）的变化均呈正相关（r值分别为0.537和0.493，P〈0.05）。新诊断T2DM患者CSII治疗后血浆Lp－PLA2和sPLA2水平的改变与胰岛素抵抗改善有关，可能发挥糖尿病大血管病变的保护作用。临床试验注册 中国临床试验注册中心，ChiCTR－TRC－10001618。
The aim of the study was to explore the effect and its clinical relevance of short-term intensive insulin treatment on plasma concentrations of lipoprotein-associated phospholipase A2 （Lp-PLA2） and secretory phospholipase A2 （sPLA2） in newly diagnosed type 2 diabetes mellitus （T2DM）. Ninety newly diagnosed T2DM patients were recruited and received continuous subcutaneous insulin infusion （CSII） for about 2 weeks. After CSII, sPLA2 levels [173.78 （80.95, 278.09） μg/L] were significantly decreased compared with the levels before [219.33 （130.03, 337.30） μg/L], P〈0.01, while no statistic significant changes could be viewed in Lp-PLA2 levels. Correlation analysis showed that the changes of Lp-PLA2 and sPLA2 were both positively correlated with the changes of homeostasis model assessment of insulin resistance（HOMA-IR）after CSII （r=0.537, 0.493 respectively, all P〈0.05）. The Lp-PLA2 and sPLA2 level reduction after CSII might help to protect the patients from diabetic macroangiopathy. Trial registration Chinese Clinical Trial Registry, ChiCTR-TRC-10001618.
出处
《中华内科杂志》
CAS
CSCD
北大核心
2017年第2期127-129,共3页
Chinese Journal of Internal Medicine
基金
广东省药学会科学研究基金（2012C11）
关键词
糖尿病
2型
磷脂酶赴
Diabetes mellitus, type 2,Phospholipase A2
